# Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery

> **NCT00873002** · PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** panobinostat
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00873002
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Dose Limiting Toxicity
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00873002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00873002, "Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00873002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*